Gastric Cancer Diagnostic Market Report 2025

The gastric cancer diagnostic market size has grown strongly in recent years. It will grow from $2.59 billion in 2024 to $2.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be attributed to the rising prevalence of *Helicobacter pylori* infections, increasing awareness of gastric cancer symptoms, higher incidence of gastric cancer among aging populations, greater consumption of smoked and preserved foods, and the expanding use of diagnostic screening in high-risk groups.

The gastric cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $3.63 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to the increasing demand for early detection and screening programs, rising awareness campaigns focused on gastric cancer prevention, growing adoption of personalized medicine approaches, expansion of healthcare infrastructure in emerging markets, and heightened emphasis on non-invasive and rapid diagnostic tests. Key trends during this period include advancements in molecular diagnostic technologies, development of biomarker panels to enhance diagnostic accuracy, creation of portable point-of-care diagnostic devices, innovation in minimally invasive diagnostic tools, and integration of imaging modalities.

The rising incidence of gastric cancer is expected to drive growth in the gastric cancer diagnostic market. Gastric cancer, a malignant tumor of the stomach lining, develops when cells grow uncontrollably and can invade surrounding tissues or metastasize. The increase in cases is largely attributed to unhealthy dietary habits, including high consumption of salted, smoked, and processed foods, which damage the stomach lining and elevate cancer risk. Gastric cancer diagnostics facilitate early detection of malignant lesions, enabling timely treatment and improved patient outcomes. They enhance clinical efficiency by providing rapid and accurate results that support better disease management. For example, in May 2024, the American Cancer Society reported 26,890 new stomach cancer cases in the U.S., up from 26,500 in 2023, highlighting the growing need for effective diagnostic solutions.

Companies in this market are innovating with AI-powered endoscopic diagnostic tools to improve early detection and accuracy. AI-based endoscopic diagnostic support devices analyze video images in real time during endoscopy to detect gastrointestinal abnormalities, including early-stage cancer. In March 2024, AI Medical Service Inc., a Japan-based medical technology company, launched GastroAI-model G, which uses deep learning to highlight suspicious lesions on the endoscopic screen, alerting physicians instantly for further examination or biopsy. This innovation improves diagnostic accuracy and enables earlier intervention, which is critical for better patient outcomes.

In April 2025, SSI Diagnostica Group, a Denmark-based microbiology company, acquired Gulf Coast Scientific Corporation, a U.S.-based diagnostics firm specializing in H. pylori testing for gastric cancer risk detection. This acquisition strengthens SSI Diagnostica’s gastrointestinal disease testing capabilities, enhances its presence in the U.S. diagnostics market, and supports growth through innovation and complementary technology in gastric cancer diagnostics.

Major players in the gastric cancer diagnostic market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Qiagen N.V., DiaSorin S.p.A, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Fujirebio Inc., MiRXES Pte Ltd., BIOCEPT Inc., Pillar Biosciences Inc.

North America was the largest region in the gastric cancer diagnostic market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastric cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Gastric cancer diagnostics encompass a range of tests and procedures designed to detect and confirm the presence of cancer in the stomach. Their primary objective is to identify gastric tumors at an early stage, determine tumor type and progression, and support effective treatment planning.

The primary types of gastric cancer diagnostics include endoscopy, imaging, biopsy, laboratory tests, and biomarker-based testing. Endoscopy involves inserting a flexible tube equipped with a camera and light to visually examine internal organs and tissues. The products used in these diagnostics include reagents, consumables, and instruments, while the technologies employed range from molecular diagnostics and immunoassays to next-generation sequencing and others. These diagnostics are applied for early detection, screening, and disease monitoring, catering to a wide range of end users such as hospitals, clinics, diagnostic laboratories, and other healthcare facilities.

The gastric cancer diagnostic market research report is one of a series of new reports that provides gastric cancer diagnostic market statistics, including gastric cancer diagnostic industry global market size, regional shares, competitors with a gastric cancer diagnostic market share, detailed gastric cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic industry. This gastric cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer diagnostic market consists of revenues earned by entities by providing services such as genetic counselling, risk assessment programmes, telepathology consultations, and patient navigation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer diagnostics market also includes sales of liquid biopsy kits, rapid diagnostic test (RDT) devices, digital pathology scanners, contrast agents for imaging, and lab-on-a-chip systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.